United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

18 Jun 2019
Change (% chg)

$-0.02 (-0.26%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Greene, Barry 

Mr. Barry E. Greene is an Independent Director of Acorda Therapeutics, Inc. Mr. Greene currently serves as President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc. Mr. Greene joined Alnylam in September 2003, bringing over 15 years of experience in the healthcare industry and in consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful approval and launch of VELCADE (bortezomib) in mid-2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene’s past experiences included being Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck); Vice President Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and partner of Andersen Consulting, responsible for the pharmaceutical/biotechnology marketing and sales practice. He is currently Lead Director of the board of directors of Karyopharm Therapeutics Inc., where he serves as Chair of the Compensation Committee, and a member of the Compliance Committee. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and serves as a Senior Scholar at Duke University, Fuqua School of Business. Mr. Greene brings to our Board extensive experience in the healthcare industry as well as practical experience guiding new drugs through the commercialization process. Based on this experience, Mr. Greene serves as Chair of our Ad Hoc Business Development Committee.

Basic Compensation

Total Annual Compensation, USD 72,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 94,516
Fiscal Year Total, USD 166,516

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen


Richard Batycky


David Lawrence


Jane Wasman


Burkhard Blank


Lauren Sabella

As Of  30 Dec 2017